Sponsor Check › Collplant Biotechnologies › Issuer
Corporation · organized in ISRAEL · formed Over five years ago · REHOVOT, L3 · SEC CIK 1631487
Part of sponsor group: Collplant Biotechnologies (2 issuers, 21 filings) · grouped because: shared people · confidence 100% · Not the same sponsor? Request a correction
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Oct 22, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. State securities regulator actions: not yet searched. · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Coming soon.
What will be compared: what the sponsor says publicly (website, marketing materials, claimed profile) against what public records show — SEC Form D filings, Form ADV adviser registration, and state business records. Every comparison is reviewed by a person before it is published.
No comparisons published yet.
Sources to be compared: sponsor public claims · SEC Form D · SEC Form ADV (IAPD) · state business records · As of Oct 23, 2026, 9:14 PM ET.
4 of 7 offerings report sales commissions totalling $958,950; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Nov 3, 2017 D File 021-298090 | $0 | $0 | $0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers. | None listed |
| EDGAR ↗ | Sep 10, 2019 D File 021-348458 | $0 | $0 | $0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers and directors. | None listed |
| EDGAR ↗ | Mar 9, 2020 D File 021-362299 | $0 | $0 | $0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers and directors. | None listed |
| EDGAR ↗ | Jun 4, 2025 D File 021-547984 | $252,000 | $0 | $0 The Company intends to use the net proceeds for general corporate purposes, which may include supporting the work with its business partner regarding one of its product candidates, funding working capital and funding research and development. | H.C. Wainwright & Co. LLC BrokerCheck CRD 000000375 ↗ |
| EDGAR ↗ | Feb 17, 2026 D File 021-573643 | $210,950 (est.) | $0 | $0 (est.) The Company intends to use the net proceeds for general corporate purposes, which may include but are not limited to, working capital and funding research and development programs. | H.C. Wainwright & Co. LLC BrokerCheck CRD 000000375 ↗ |
| EDGAR ↗ | Jul 20, 2026 D File 021-591492 | $272,000 (est.) | $0 | $0 (est.) The Company intends to use net proceeds for general corporate purposes, including working capital, R&D programs, and evaluating strategic business combinations and other strategic transactions, the amount of which cannot currently be estimated. | H.C. Wainwright & Co., LLC BrokerCheck CRD 000000375 ↗ |
| EDGAR ↗ | Oct 22, 2026 D File 021-602262 | $224,000 (est.) | $0 | $0 (est.) The Company intends to use the net proceeds from the Offering for general corporate purposes including working capital and funding its research and development programs. | H.C. Wainwright & Co., LLC BrokerCheck CRD 000000375 ↗ Rodman & Renshaw, LLC BrokerCheck CRD 000281264 ↗ |
As reported by the issuer on Form D (Items 12–15), latest filing per offering. "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates.
Each filing as reported by the issuer. Open a row for the full plain-English detail.
| Filing | Form D filed Oct 22, 2026 SEC file no. 021-602262 · accession 0001213900-26-111756 |
|---|---|
| Raise progress | $9,249,958 sold of $9,249,958 offered (100%) · $0 remaining Including the exercise price of ordinary shares underlying such warrants at an exercise price of $3.74. The total offering amount excludes placement agent warrants (see Item 15). |
| Filing timing | Date of first sale: Oct 9, 2026 · Form D filed: Oct 22, 2026 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 15 days (0.0 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: ordinary warrants to purchase ordinary shares, including underlying ordinary shares upon exercise. |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | H.C. Wainwright & Co., LLC — FINRA BrokerCheck CRD 000000375 ↗ Rodman & Renshaw, LLC — FINRA BrokerCheck CRD 000281264 ↗ |
| Money to insiders | Sales commissions: $224,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) Sales Commission includes cash placement fee. Other comp. included management fee, a $35,000 expense allowance, reimbursement of $50,000 for legal fees, $15,950 in clearing fees, and 59,358 warrants with an ex. price of $4.675/share. · The Company intends to use the net proceeds from the Offering for general corporate purposes including working capital and funding its research and development programs. |
| Signed by | Eran Rotem, Deputy Chief Executive Officer and Chief Financial Officer (Oct 22, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $9,249,958. Typical range: $829,831–$9,999,998. Investors: 5. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed Jul 20, 2026 SEC file no. 021-591492 · accession 0001213900-26-079611 |
|---|---|
| Raise progress | $10,400,000 sold of $10,400,000 offered (100%) · $0 remaining Including the exercise price of ordinary shares underlying such warrants at an exercise price of $0.34. The total offering amount excludes placement agent warrants (see Item 15). |
| Filing timing | Date of first sale: Jul 6, 2026 · Form D filed: Jul 20, 2026 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 110 days (0.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Series A warrants and series B warrants to purchase ordinary shares, including underlying ordinary shares upon exercise. |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | H.C. Wainwright & Co., LLC — FINRA BrokerCheck CRD 000000375 ↗ Solicits in: FL, NY, TX |
| Money to insiders | Sales commissions: $272,000 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) Includes placement and management fees, $35,000 non-accountable expense allowance, reimbursement of up to $50,000 legal fees and $15,950 clearing expenses, and warrants exercisable upon shareholder approval for 458,824 ordinary shares at $0.425/share. · The Company intends to use net proceeds for general corporate purposes, including working capital, R&D programs, and evaluating strategic business combinations and other strategic transactions, the amount of which cannot currently be estimated. |
| Signed by | Eran Rotem, Deputy Chief Executive Officer and Chief Financial Officer (Jul 20, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $10,400,000. Typical range: $829,831–$9,999,998. Investors: 5. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Feb 17, 2026 SEC file no. 021-573643 · accession 0001213900-26-016910 |
|---|---|
| Raise progress | $4,000,000 sold of $4,000,000 offered (100%) · $0 remaining Offering of unregistered series A warrants to purchase 1,600,000 ordinary shares, and unregistered series B warrants to purchase 1,600,000 ordinary shares. The total offering amount does not reflect warrants issued to placement agent (see Item 15). |
| Filing timing | Date of first sale: Feb 4, 2026 · Form D filed: Feb 17, 2026 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 262 days (0.7 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 8 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Series A warrants and series B warrants to purchase ordinary shares, including underlying ordinary shares upon exercise. |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | H.C. Wainwright & Co. LLC — FINRA BrokerCheck CRD 000000375 ↗ Solicits in: FL, IL, NV, NY |
| Money to insiders | Sales commissions: $210,950 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 (est.) H.C. Wainwright is entitled to 7.0% of gross proceeds cash fee, 1.0% of gross proceeds management fee, $35,000 non-accountable expenses, $15,950 clearing fees and warrants to purchase 96,000 ordinary shares at $1.5625/share for 5 years. This is estimated. · The Company intends to use the net proceeds for general corporate purposes, which may include but are not limited to, working capital and funding research and development programs. |
| Signed by | Eran Rotem, Deputy Chief Executive Officer and Chief Financial Officer (Feb 17, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $4,000,000. Typical range: $829,831–$9,999,998. Investors: 8. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Jun 4, 2025 SEC file no. 021-547984 · accession 0001213900-25-050961 |
|---|---|
| Raise progress | $3,870,006 sold of $3,870,006 offered (100%) · $0 remaining The warrants and shares underlying the warrants, were issued in connection with an offering of (i) 1,200,002 ordinary shares issued in a registered direct offering, and (ii) unregistered warrants to purchase 1,272,002 ordinary shares. |
| Filing timing | Date of first sale: May 29, 2025 · Form D filed: Jun 4, 2025 (6 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 513 days (1.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 4 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | H.C. Wainwright & Co. LLC — FINRA BrokerCheck CRD 000000375 ↗ Solicits in: CA, FL, IL, NY |
| Money to insiders | Sales commissions: $252,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 H.C. Wainwright is also entitled to 1.0% of the gross proceeds as management fee, $85,000 for non-accountable expenses, $15,950 for clearing fees and warrants to purchase 72,000 ordinary shares exercisable at $3.75 per share for 3.5 years. · The Company intends to use the net proceeds for general corporate purposes, which may include supporting the work with its business partner regarding one of its product candidates, funding working capital and funding research and development. |
| Signed by | Eran Rotem, Deputy Chief Executive Officer and Chief Financial Officer (Jun 4, 2025) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $3,870,006. Typical range: $829,831–$9,999,998. Investors: 4. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Mar 9, 2020 SEC file no. 021-362299 · accession 0001213900-20-005755 |
|---|---|
| Raise progress | $4,450,000 sold of $4,450,000 offered (100%) · $0 remaining |
| Filing timing | Date of first sale: Mar 2, 2020 · Form D filed: Mar 9, 2020 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,427 days (6.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 14 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers and directors. |
| Signed by | Eran Rotem, Deputy CEO and Chief Financial Officer (Mar 9, 2020) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $4,450,000. Typical range: $829,831–$9,999,998. Investors: 14. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Sep 10, 2019 SEC file no. 021-348458 · accession 0001213900-19-017636 |
|---|---|
| Raise progress | $3,500,000 sold of $3,500,000 offered (100%) · $0 remaining |
| Filing timing | Date of first sale: Aug 30, 2019 · Form D filed: Sep 10, 2019 (11 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,612 days (7.2 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 8 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers and directors. |
| Signed by | Eran Rotem, Deputy CEO and Chief Financial Officer (Sep 10, 2019) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $3,500,000. Typical range: $829,831–$9,999,998. Investors: 8. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Nov 3, 2017 SEC file no. 021-298090 · accession 0001104659-17-066050 |
|---|---|
| Raise progress | $2,000,000 sold of $5,000,000 offered (40%) · $3,000,000 remaining |
| Filing timing | Date of first sale: Oct 26, 2017 · Form D filed: Nov 3, 2017 (8 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 3,285 days (9.0 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Industry / issuer size | Other Health Care · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 Issuer expects to use proceeds from the offering for working capital purposes which includes payment of salaries to the named executive officers. |
| Signed by | Eran Rotem, Chief Financial Officer (Nov 3, 2017) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$54,310. Offering size: $5,000,000. Typical range: $829,831–$9,999,998. Investors: 1. Typical range: 2–15. "Similar" = Other Health Care offerings claiming 506(b) filed in the last 5 years (4,189 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
All Form D filings for this CIK on SEC EDGAR ↗. History: 3 new offerings in the last 12 months · most recent filing Oct 22, 2026.
| Name | Relationship | Address state | On filings | Also listed on |
|---|---|---|---|---|
| Abraham Havron | Director | L3 | Nov 3, 2017 → Oct 22, 2026 | 1 other issuer |
| Alisa Lask | Director | L3 | Feb 17, 2026 → Oct 22, 2026 | — |
| Bar Abelis | Executive Officer Vice President, Legal | L3 | Feb 17, 2026 → Oct 22, 2026 | — |
| Bowman Bagley | Executive Officer Vice President, Commercial North America | L3 | Feb 17, 2026 → Oct 22, 2026 | — |
| Elan Penn | Director | L3 | Sep 10, 2019 → Oct 22, 2026 | 1 other issuer |
| Eran Rotem | Executive Officer Deputy Chief Executive Officer and Chief Financial Officer | L3 | Nov 3, 2017 → Oct 22, 2026 | — |
| Hugh Evans | Director | L3 | Feb 17, 2026 → Oct 22, 2026 | — |
| Jasmine Seror | Executive Officer Vice President, Product Development | L3 | Feb 17, 2026 → Oct 22, 2026 | — |
| Joseph Zarzewsky | Director | L3 | Sep 10, 2019 → Oct 22, 2026 | 1 other issuer |
| Oren Fahimipoor | Executive Officer Vice President, Operations | L3 | Jun 4, 2025 → Oct 22, 2026 | — |
| Philippe Bensimon | Executive Officer Vice President, Regulatory Affairs and Quality Assurance | L3 | Nov 3, 2017 → Oct 22, 2026 | — |
| Ruti Ben Shlomi | Executive Officer, Director Chief Executive Officer of Lightsolver Ltd., the Issuer's subsidiary. | L3 | Oct 22, 2026 | — |
| Yehiel Tal | Executive Officer, Director Chief Executive Officer and Interim Chairman of the Board of Directors | L3 | Nov 3, 2017 → Oct 22, 2026 | — |
| Abraham Dreiher Havron | Director | L3 | Jun 4, 2025 | 1 other issuer |
| Alisa Dreiher Lask | Director | L3 | Jun 4, 2025 | — |
| Elan Dreiher Penn | Director | L3 | Jun 4, 2025 | 1 other issuer |
| Elana Gazal | Executive Officer Vice President, Research and Development | L3 | Jun 4, 2025 | — |
| Hadas Dreiher Horowitz | Executive Officer Vice President, Human Resources | L3 | Jun 4, 2025 | — |
| Hugh Dreiher Evans | Director | L3 | Jun 4, 2025 | — |
| Joseph Dreiher Zarzewsky | Director | L3 | Jun 4, 2025 | 1 other issuer |
| Roger Dreiher Pomerantz | Director | L3 | Jun 4, 2025 | — |
| Gili Hart | Director | L3 | Nov 3, 2017 → Mar 9, 2020 | — |
| Ilana Belzer | Executive Officer | L3 | Nov 3, 2017 → Mar 9, 2020 | 1 other issuer |
| Nadav Orr | Executive Officer | L3 | Nov 3, 2017 → Mar 9, 2020 | — |
| Roger Pomerantz | Director | L3 | Mar 9, 2020 | — |
| Adi Goldin | Director | L3 | Nov 3, 2017 → Sep 10, 2019 | 1 other issuer |
| Scott Burrell | Director | L3 | Nov 3, 2017 → Sep 10, 2019 | — |
| Wolfgang Ruttenstorfer | Director | L3 | Sep 10, 2019 | — |
| David Tsur | Director | L3 | Nov 3, 2017 | 1 other issuer |
| Oded Shoseyov | Executive Officer | L3 | Nov 3, 2017 | — |
| Shomrat Shurtz | Executive Officer | L3 | Nov 3, 2017 | — |
Executive officers, directors and promoters as self-reported by the issuer. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Other issuers listing the same people:
Shared address: this business address appears on no other issuer's filings in our index.
Not yet searched. Sources to be searched: SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected. We store official links only (company website, verified via a profile claim) and the earliest archived date of the website; never personal or family accounts.
Export this report as PDF (all source links + data timestamp; members)
No corrections have been requested for this page.
The complete public-record profile for CollPlant Biotechnologies Ltd, plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.